A review of 6 placebo-controlled medical trials with one,134 complete contributors concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) had been affiliated with a increased common improvement around the Ashworth scale for spasticity in multiple sclerosis individuals in comparison with placebo, While this didn't reach statistical signif